Updated:
Huma Therapeutics
Huma Therapeutics GmbH is a digital health company based in Munich, Germany.
Huma Therapeutics
Huma Therapeutics GmbH is a digital health company based in Munich, Germany. The firm was founded to build a cloud-based platform that uses AI and patient-reported data to monitor health conditions remotely. Its technology is designed to support both clinical research and routine care, with a stated mission to shift healthcare from episodic to continuous monitoring. The company's platform serves multiple asset classes within digital health: remote monitoring for chronic diseases such as heart failure and diabetes, decentralized clinical trials for pharmaceutical sponsors, and predictive analytics using machine learning. Huma has partnered with hospitals and drug developers across Europe and Asia. The firm has disclosed collaborations with the UK's National Health Service and pharmaceutical companies including Roche and Bayer (per company press releases and public records). Huma's team includes engineers, data scientists, and clinical researchers based primarily in Munich, with additional operations in London and other European hubs. The company has raised capital from venture investors including Bayer and Samsung, though current AUM and professional headcount are not publicly disclosed. The firm also engages in research partnerships with academic institutions to validate its AI algorithms. Structurally, Huma is an operating company rather than an investment vehicle, generating revenue from software subscriptions and service fees. Its business model integrates AI-driven diagnostics with clinical workflow, differentiating it from pure-play research firms.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Munich
Corporate office
Munich, Germany
Sector focus
Frequently asked questions
What is Huma Therapeutics' core product?
Huma operates a cloud-based platform that collects patient-reported data from wearable devices and mobile apps, using AI to predict clinical deterioration. The platform supports both chronic disease management and decentralized clinical trials, replacing some in-person visits with remote monitoring (per the firm's public communications).
Who are Huma Therapeutics' main partners?
Huma has disclosed partnerships with the UK's National Health Service, as well as pharmaceutical companies Roche and Bayer (per public records and press releases). These collaborations deploy Huma's technology in clinical settings and drug trials across Europe and Asia.
Is Huma Therapeutics a family office or an operating company?
Huma is an operating company, not a family office or investment firm. It generates revenue from software licensing and service agreements with hospitals, pharmaceutical companies, and clinical research organizations. No investment mandate or asset management function is associated with the firm.
What diseases does Huma's platform target?
Huma's platform is primarily used for chronic conditions including heart failure, diabetes, and hypertension. The company also supports post-operative recovery monitoring and decentralized trials for conditions such as Parkinson's disease (per public disclosures and press materials).
Where does Huma Therapeutics operate geographically?
Huma is headquartered in Munich, Germany, with additional offices reported in London. Its platform is deployed in hospitals and research centers across Germany, the UK, and several countries in Asia (per company announcements and public records).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: